换一批
换一批Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.
第一作者：
Francesco,Passiglia
第一单位：
Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, Palermo University Hospital, Palermo, Italy.
作者：
主题词
抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤药(Antineoplastic Agents);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);临床试验, Ⅱ期(主题)(Clinical Trials, Phase II as Topic);临床试验, Ⅲ期(主题)(Clinical Trials, Phase III as Topic);人类(Humans);发病率(Incidence);肺肿瘤(Lung Neoplasms);肺炎(Pneumonia);随机对照试验(主题)(Randomized Controlled Trials as Topic);存活率分析(Survival Analysis);紫杉烷类(Taxoids);治疗结果(Treatment Outcome)
DOI
10.1002/ijc.31136
PMID
29080213
发布时间
2022-04-10
- 浏览12
International journal of cancer
1277-1284页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
